3[4]Li JT, Lu Y, Hou J, et al. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial[J]. Clin Infect Dis, 1997,24:498-505 被引量：1
4[5]Yoshida T, Oono Y, Toyoda M, et al. Efficacy of sulbactam/cefoperazone in respiratory tract infections in elderly patients with underlying respiratory diseases[J]. Jpn J Antibiot, 1996,49:710-714 被引量：1
6Sanders CC, Barry AL, Washington JA, et al. Detection of extended-spectrum β-lactamase-producing members of the family Enterobacteriaceae with the VITEK ESBL test[J]. J Clin Microbiol, 1996, 34(12): 2997. 被引量：1
7Jarlier V, Nicolas MH, Fournier G, et al. Extended broad-spectrum β-lactamase conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns[J]. Rev Infect Dis , 1988, 10(4): 867. 被引量：1
8Livermore DM. β-Lactamase in laboratory and clinical resistance[J]. Clin Microbiol Rev, 1995, 8(4): 557. 被引量：1
